Timothy Y. Y. Lai

Prof. Timothy Y. Y. Lai

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Ophthalmology
Verified
Journal Article
Closed access
MMMichael F Marmor
Michael F Marmor
UKUlrich Kellner
Ulrich Kellner
TLTimothy Y. Y. Lai
Timothy Y. Y. Lai
RMRonald B Melles
Ronald B Melles
WMWilliam F Mieler
William F Mieler
AOAmerican Academy Of Ophthalmology
American Academy Of Ophthalmology

11 July 2018 in Eye
Verified
Journal Article
Closed access
PDF file
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
WLWon Ki Lee
Won Ki Lee
HKHideki Koizumi
Hideki Koizumi
KDKunal Dansingani
Kunal Dansingani
TLTimothy Y. Y. Lai
Timothy Y. Y. Lai
KFK. Bailey Freund
K. Bailey Freund

1 February 2011 in Ophthalmology
Verified
Journal Article
Closed access
MMMichael F. Marmor
Michael F. Marmor
UKUlrich Kellner
Ulrich Kellner
TLTimothy Y. Y. Lai
Timothy Y. Y. Lai
JLJonathan S. Lyons
Jonathan S. Lyons
WMWilliam F. Mieler
William F. Mieler

1 September 2012 in Retina
Verified
Journal Article
Closed access
AKAdrian Koh
Adrian Koh
WLWon Ki Lee
Won Ki Lee
LCLee-Jen Chen
Lee-Jen Chen
SCShih-Jen Chen
Shih-Jen Chen
YHYehia Hashad
Yehia Hashad
TLTock H. Lim
Tock H. Lim
To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months.

1 May 2016 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
KOKyoko Ohno-Matsui
Kyoko Ohno-Matsui
TLTimothy Y. Y. Lai
Timothy Y. Y. Lai
CLChi-Chun Lai
Chi-Chun Lai
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung

1 November 2019 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
TRThomas J. van Rijssen
Thomas J. van Rijssen
EDElon H.C. van Dijk
Elon H.C. van Dijk
SYSuzanne Yzer
Suzanne Yzer
KOKyoko Ohno-Matsui
Kyoko Ohno-Matsui
JKJan E.E. Keunen
Jan E.E. Keunen
CBCamiel Boon
Camiel Boon
Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20-60 years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of interventions have been proposed, reflecting the controversy associated with treating this disease. The recent publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more evidence-based approach when considering treatment options. The aim of this review is to provide a comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse laser treatment have been reported as being effective. Currently, however, the available evidence suggests that half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon patient-specific characteristics.